PE
PEPG.US PepGen Ltd
- Market cap
- USD 411M
- P/E
- -
- P/B
- 2.93x
- ROE
- -71.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PEPG.US undervalued?
Graham numberThe Graham number of PepGen Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PepGen Ltd fundamental analysis
No fundamental analysis for PepGen Ltd yet.
PepGen Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open la…
Full company profilePepGen Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PepGen Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -106K | -110K | -178K | -493K | -1.18M | -1.51M | -1.40M | - |
| Operating Income | -1.35M | -1.88M | -27.1M | -68.3M | -84.8M | -97.7M | -93.6M | -77.7M |
| EBITDA | -1.25M | -1.77M | -27.1M | -67.8M | -77.4M | -89.1M | -88.2M | -69.6M |
| Net Income | -1.35M | -1.89M | -27.3M | -69.1M | -78.6M | -90.0M | -89.7M | -73.3M |
| EPS | -0.06 | -0.08 | -1.22 | -4.42 | -3.30 | -2.85 | -2.12 | -1.06 |
| Balance Sheet | ||||||||
| Total Assets | 4.19M | 10.6M | 144M | 217M | 143M | 151M | 174M | 128M |
| Total Liabilities | 326K | 868K | 10.5M | 37.8M | 34.6M | 32.3M | 26.5M | 24.7M |
| Shareholders' Equity | 3.87M | 9.77M | 133M | 180M | 108M | 119M | 147M | 103M |
| Cash & Short-term Investments | 3.49M | 9.78M | 133M | 182M | 110M | 120M | 148M | 105M |
| Total Debt | - | - | - | 24.5M | 20.1M | 18.7M | 17.0M | 15.6M |
| Cash Flow | ||||||||
| Operating Cash Flow | -885K | -1.65M | -22.6M | -59.3M | -69.0M | -82.4M | -81.6M | -63.2M |
| Capital Expenditure | 29.0K | 8.00K | 500K | 3.76M | 2.60M | 497K | 264K | 40.0K |
| Free Cash Flow | -914K | -1.66M | -23.1M | -63.0M | -71.6M | -82.9M | -81.9M | -63.2M |
| Ratios | ||||||||
| ROE | -34.8% | -19.3% | -20.5% | -38.5% | -72.5% | -75.9% | -60.8% | -71.1% |
| ROA | -32.1% | -17.8% | -19.0% | -31.8% | -55.0% | -59.6% | -51.6% | -57.4% |
| Debt to Equity | - | - | - | 0.14x | 0.19x | 0.16x | 0.12x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
PepGen Ltd dividends
PepGen Ltd has not paid dividends in the last 7 fiscal years.
Who owns PepGen Ltd
- Insiders 0.20%
- Institutions 63.23%
- Public & others 36.57%
- Shares outstanding 94.3M
- Free float 36.1M
Top funds holding PEPG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.41M | 2.04% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 495K | 0.72% | -0.19% | Oct 2026 |
| Fidelity Extended Market Index | 211K | 0.31% | -9.03% | Sep 2026 |
| iShares Micro-Cap ETF | 128K | 0.19% | 0.00% | Oct 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 100K | 0.15% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 86.1K | 0.13% | -0.05% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 83.7K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 69.2K | 0.10% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 65.4K | 0.09% | +0.21% | Oct 2026 |
| Vifag 2002 SICAV | 50.0K | 0.07% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 49.0K | 0.07% | +2.51% | Oct 2026 |
| Vanguard Balanced Index Inv | 26.7K | 0.04% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 20.2K | 0.03% | +47.42% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 19.9K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 17.7K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 16.2K | 0.02% | -63.09% | Aug 2026 |
| Dimensional US Small Cap ETF | 13.3K | 0.02% | 0.00% | Oct 2026 |
| Dimensional Global Core Equity USD Acc | 12.2K | 0.02% | +192.05% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 11.7K | 0.02% | 0.00% | Oct 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 11.0K | 0.02% | -1.73% | Jun 2026 |
Top institutions holding PEPG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 20.1M | 29.13% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 4.48M | 6.50% | 0.00% | Jun 2026 |
| Viking Global Investors LP | 3.48M | 5.06% | 0.00% | Jun 2026 |
| LAURION CAPITAL MANAGEMENT LP | 2.75M | 3.99% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.59M | 3.76% | +61.17% | Jun 2026 |
| Vivo Capital, LLC | 2.33M | 3.38% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.94M | 2.81% | -0.09% | Jun 2026 |
| Millennium Management LLC | 1.79M | 2.59% | -14.06% | Jun 2026 |
| BlackRock Inc | 1.30M | 1.89% | +2.07% | Jun 2026 |
| Renaissance Technologies Corp | 881K | 1.28% | -42.06% | Sep 2026 |
| Marshall Wace Asset Management Ltd | 867K | 1.26% | +190.38% | Jun 2026 |
| GSA Capital Partners LLP | 853K | 1.24% | +2,127.58% | Jun 2026 |
| Citadel Advisors Llc | 658K | 0.96% | +216.65% | Jun 2026 |
| Awm Investment Company Inc | 600K | 0.87% | -67.23% | Jun 2026 |
| MONIMUS CAPITAL MANAGEMENT, LP | 588K | 0.85% | -1.83% | Jun 2026 |
| Squarepoint Ops LLC | 529K | 0.77% | +260.91% | Jun 2026 |
| Geode Capital Management, LLC | 523K | 0.76% | -2.34% | Jun 2026 |
| Creek Drive Management Group LLC | 450K | 0.65% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 447K | 0.65% | 0.00% | Jun 2026 |
| Diadema Partners LP | 373K | 0.54% | +147.33% | Jun 2026 |
PepGen Ltd company profile
- Company name
- PepGen Ltd
- Ticker
- PEPG.US
- Exchange
- USA Stocks
- Listed since
- May 6, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 56
- Fiscal year end
- December
- Address
- 321 Harrison Avenue, Boston, MA, United States, 02118
- Phone
- 781 797 0979
- Website
- pepgen.com
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PepGen Ltd management
10- Dr. James G. McArthur Ph.D.President, CEO, Treasurer, Secretary & Director · born 1962
- Mr. Noel P. Donnelly M.B.A.Chief Financial Officer · born 1970
- Mr. Joseph D. Vittiglio Esq., J.D.Chief Business & Legal Officer and Secretary · born 1972
- Dr. Kasra Kasraian Ph.D.Chief Technical Officer · born 1967
- Ms. Emiko BryantSenior Vice President of HR & Administration
- Dr. Hayley Parker Ph.D.Senior Vice President of Global Regulatory Affairs & Quality
- Dr. Paul D. Streck M.B.A., M.D.Executive VP and Head of Research & Development · born 1964
- Ms. Pallavi Lonkar Ph.D.Vice President & Head of Preclinical
- Ms. Melissa MichaelsExecutive Director & Head of Regulatory Affairs CMC
- Mr. Michael ZhaoVice President & Head of Biometrics